Sanofi among top performers as Jefferies reiterates Buy rating
Sanofi is standing out at the top of the CAC 40 with a 3.10% gain to 75.80 euros, bolstered by Jefferies maintaining its Buy recommendation. The firm set a price target of 100 euros, representing a 36% upside potential compared to Wednesday's close.
The U.S. investment bank praised the French pharmaceutical giant for continuing to advance its immunology franchise through a broad and expanding late-stage pipeline. This pipeline notably includes five Phase III programs, with the potential to increase to eight in the near term.
In another positive takeaway, long-term prospects for vaccines remain robust despite short-term regulatory scrutiny. Management remains confident in the longer-term outlook, noting that 'the prevalence of infectious diseases is still very real and increasing,' even though the last two flu seasons were the 'worst' observed in the past 16 years.
The group aims to push the vaccination coverage rate for Beyfortus (a vaccine designed to prevent respiratory syncytial virus infections in infants and young children) beyond the current 55%. Jefferies views this as a key asset to watch.
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases;
- human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2025, the group had 37 production sites worldwide.
Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
